Nanovalent Presents New Data at Biotech Showcase 2021 Including Significant GMB Data

Bozeman, Montana--(Newsfile Corp. - January 11, 2021) -  Nanovalent Pharmaceuticals has been selected to present at the 2021 Biotech Showcase, a premier investor conference held each year during the week of the JP Morgan Healthcare Investment Week. This year, the conferences will be held digitally, and Nanovalent will have a pre-recorded presentation available beginning January 11, 2021. The Biotech Showcase is designed to get presenting companies and funded technologies in front of potential investors and strategic partners.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Lead drug candidate on schedule to an IND/BLA and the clinic in 2021
  • Nanovalent issued US patent relating to its application of targeted polymerized nanoparticles in cancer.
  • 891K NIH Grant for NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/71764_figure1_550.jpg

Click image above to view full announcement.


About NanoValent Pharmaceuticals, Inc.

NanoValent Pharmaceuticals, Inc., founded in 2006, is a privately-held company focused on the development and commercialization of a new generation of Targeted Nanospheres (TNS). Working in close collaboration with Children's Hospital Los Angeles (CHLA), NanoValent aims to develop superior therapeutics for patients restricted by current treatment options and working with other pharmaceutical companies to optimize or expand the utility of additional therapeutics.

The company's proprietary platform technology is an important, new tool that can potentially improve the efficacy and safety of a wide range of therapeutic molecules and biologics. The targeting options and flexibility of the platform make potential applications almost limitless. NanoValent's leading drug candidate, NV103 (anti-CD99, irinotecan), is approaching phase I clinical trials with initial validating programs including Ewing Sarcoma, Hepatocellular Carcinoma, Neuroendocrine tumors, Acute Myeloid Leukemia (AML), and Acute Lymphoblastic Leukemia (ALL). Other cancer therapeutic candidates include NV101 (anti-CD99, doxorubicin) and NV102 (anti-CD19, doxorubicin).

Funding has come from direct management investment, angel investors, and significant grants from the National Science Foundation, the National Cancer Institute, and the Montana Chamber of Commerce. Please visit http://www.nanovalent.com for more information.

Contacts:

Timothy Enns
(925) 719-2143
time@nanovalent.com

Source: Nanovalent Pharmaceuticals

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71764

info